Sales of Johnson’s Baby Powder Halted in US, Canada
Johnson & Johnson says talc-based powder is safe and will still be sold in other countries.
Gynecologic Cancers
Lynparza Plus Bevacizumab Approved for First-Line Maintenance in HRD-Positive Advanced Ovarian Cancer
The FDA has approved Lynparza® for use in combination with bevacizumab as first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
Zejula Approved for Maintenance Treatment of Advanced Ovarian Cancer
Results showed a statistically significant improvement in PFS for Zejula compared with placebo, regardless of biomarker status.
New Dosing Schedule Approved for All Keytruda Indications
The FDA has approved the supplemental Biologics License Application (sBLA) for Keytruda® (Merck) to include an additional recommended dosage of 400mg every 6 weeks across all adult indications.
ASCO Guideline: Germline Testing Recommended for All Women Diagnosed With Epithelial Ovarian Cancer
A pervading theme of this guideline was the importance of including genetic counselors in the interpretation and communication of germline and somatic testing results.
Use of Powder in Genital Area Not Linked to Ovarian Cancer
Frequent vs never use, long-term versus never use not significantly associated with higher risk.
Studies Confirm Safety of 9-Valent HPV Vaccination
Studies based on searching Vaccine Adverse Event Reporting System, six Vaccine Safety Datalink sites
J&J Says No Asbestos Detected in New Tests of Baby Powder
Tests were performed by two third-party laboratories as part of the company’s ongoing investigation.
MPR Weekly Dose Podcast: Episode 10
This week we talk about the resurrection of Biogen’s novel Alzheimer treatment; A “landmark” approval in cystic fibrosis; Expanded indication for Farxiga; The first topical minocycline formulation for acne vulgaris; and the Johnson & Johnson baby powder recall.
Zejula Approved for Late-line Treatment of Recurrent Ovarian Cancer
Zejula, a poly(ADP-ribose) polymerase (PARP) inhibitor, is also approved for maintenance treatment in adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
